<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the neuroprotective effects <z:chebi fb="0" ids="2668">amlodipine</z:chebi> and/or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> in <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MetS) <z:chebi fb="3" ids="16646">Zucker</z:chebi> fatty rats against transient (90 min) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>The rats were pretreated with vehicle, <z:chebi fb="0" ids="2668">amlodipine</z:chebi>, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, or <z:chebi fb="0" ids="2668">amlodipine</z:chebi> plus <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> for 28 days, and 24 hr after transient MCAO the <z:mpath ids='MPATH_124'>infarct</z:mpath> size was assessed via <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin staining, and terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi>-<z:chebi fb="1" ids="15956">biotin</z:chebi> in situ nick end labeling (TUNEL) and microtubule-associated protein 1 light chain 3 (LC3) expression were examined by immunohistochemistry to evaluate <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and autophagy, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Compared with the vehicle group, rats treated with <z:chebi fb="0" ids="2668">amlodipine</z:chebi> or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> alone showed a significant decrease in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (P &lt; 0.01), which was further decreased in the <z:chebi fb="0" ids="2668">amlodipine</z:chebi> plus <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> group (P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the vehicle group, the numbers of TUNEL- and LC3-positive cells were markedly reduced by <z:chebi fb="0" ids="2668">amlodipine</z:chebi> or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> alone (P &lt; 0.01) and further decreased by <z:chebi fb="0" ids="2668">amlodipine</z:chebi> plus <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>The number of apoptotic TUNEL/autophagic LC3 double-positive cells was also significantly decreased with <z:chebi fb="0" ids="2668">amlodipine</z:chebi> or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> alone compared with vehicle (P &lt; 0.01) and was further decreased by <z:chebi fb="0" ids="2668">amlodipine</z:chebi> plus <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>These data suggest additive neuroprotective effects of combination <z:chebi fb="0" ids="2668">amlodipine</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treatment after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in MetS model <z:chebi fb="3" ids="16646">Zucker</z:chebi> rats </plain></SENT>
<SENT sid="6" pm="."><plain>These effects are mediated, at least in part, via antiapoptotic and antiautophagic mechanisms </plain></SENT>
<SENT sid="7" pm="."><plain>Further studies are now needed to expand these preliminary results to understand fully the mechanisms involved in the protective effects of <z:chebi fb="0" ids="2668">amlodipine</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> against <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>